


US application Serial No. 09/840,503
Attorney Docket No. QA231

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. - 9. (Canceled).
10. (Previously Amended) A compound of formula (I)



(I)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

X¹ is C=O;

X² is CR³;

X³ is -NH-;

X⁴ is CR⁴;

X⁵ is CR⁵;

X⁶ is CR⁶;

R¹ is alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl, or heteroaryl, provided that when R¹ is alkyl, substituted alkyl or alkenyl, R² is not cyano;

R² is cyano or a substituted or unsubstituted monocyclic heteroaryl group, provided that when R² is cyano R¹ is not alkyl, substituted alkyl or alkenyl;

R³ is hydrogen, hydroxy, halogen, cyano, CO₂R⁷, NR⁸R⁹, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocycloalkyl or heteroaryl;

R⁴, R⁵, and R⁶ are independently selected from the group consisting of hydrogen, halogen, nitro, cyano,

US application Serial No. 09/840,503
Attorney Docket No. QA231


O-R⁷, NR⁸R⁹, SR⁷, S(O)R⁷, SO₂R⁷, SO₃R⁷, SO₂NR⁸R⁹, CO₂R⁷, C(O)NR⁸R⁹, C(O)alkyl, C(O)substituted alkyl, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl and substituted alkynyl;

R⁷, R¹⁰, and R¹¹, are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O) substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocycloalkyl, C(O)heteroaryl, aryl, substituted aryl, heterocycloalkyl and heteroaryl; and


R⁸ and R⁹ are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, alkynyl, C(O)alkyl, C(O)substituted alkyl, C(O)cycloalkyl, C(O)substituted cycloalkyl, C(O)aryl, C(O)substituted aryl, C(O)Oalkyl, C(O)Osubstituted alkyl, C(O)heterocycloalkyl, C(O)heteroaryl, aryl, substituted aryl, heterocycloalkyl, and heteroaryl or R⁸ and R⁹ taken together with the nitrogen atom to which they are attached complete a heterocycloalkyl or heteroaryl ring[;]

with the following proviso[s]:

- (a) ~~when R¹ is substituted or meta-unsubstituted phenyl, R² is H, R⁴ is H, R⁵ is H and R⁶ is H, then R³ is not PhCONH,~~



- (b) ~~when R¹ is phenyl substituted with H, F, Cl, Br, I, CH₃, CF₃, OH, OCH₃, OCF₃, OCH₂CH₃, NH₂, NHCH₃, N(CH₃)₂, O-benzyl, C(=O)R₀, or C(=O)OR₀ and R₀ is a lower alkyl group, R² is H, R⁴ is H, R⁵ is H and R⁶ is H, then R³ is not~~




~~where Y is CH₂, O or S, m and n are each greater than 1, and the sum of m and n is between 3 and 6; and~~

US application Serial No. 09/840,503
Attorney Docket No. QA231

(c) when R^2 is heteroaryl, at least one of the heteroatoms must be O.

11. (Canceled)

12. (Previously Amended) A compound of Claim 10 of formula (III)



or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

R^2 is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl;

R^3 is hydrogen, hydroxy, NR^8R^9 , alkyl of 1 to 4 carbons, alkenyl of 2 to 4 carbons, alkynyl of 2 to 4 carbons, substituted alkyl of 1 to 4 carbons, phenyl, substituted phenyl, cycloalkyl of 5 to 7 carbons, substituted cycloalkyl of 5 to 7 carbons, monocyclic heterocycloalkyl and monocyclic heteroaryl;

R^4 is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, CF_3 , OCF_3 , OCH_3 , SCH_3 , $S(O)CH_3$, or $S(O)_2CH_3$;

R^5 is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, vinyl, CF_3 , CF_2CF_3 , $CH=CF_2$, OCH_3 , OCF_3 , $OCHF_2$, SCH_3 , $S(O)CH_3$, or $S(O)_2CH_3$; and

R^6 is hydrogen, halogen, nitro, hydroxy, alkyl of 1 to 4 carbons, cyano, CF_3 , OCH_3 , OCF_3 , SCH_3 , $S(O)CH_3$, and $S(O)_2CH_3$.

13. (Previously Amended) A compound of Claim 12 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

R^2 is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl, or substituted 5-oxazolyl ~~or heteroaryl~~;

R^3 is hydrogen, hydroxy, halogen, methyl or NR^8R^9 ;

US application Serial No. 09/840,503
Attorney Docket No. QA231

R^4 is hydrogen;

R^5 is halogen, methyl, ethyl, substituted alkenyl, alkyne, OMe or OCF_3 ; and

R^6 is hydrogen.

14. (Previously Amended) A compound of Claim 13 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof wherein:

R^2 is 4-oxazolyl, substituted 4-oxazolyl, 5-oxazolyl or substituted 5-oxazolyl;


R^3 is hydrogen, hydroxy, halogen or methyl;

R^4 is hydrogen;

R^5 is halogen, methyl or OMe; and

R^6 is hydrogen.

15. (Previously Amended) A compound of Claim 10 of formula (V)




(V)

or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof selected from:

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is CH_3 and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is CH_3 ;

a compound of formula (V) wherein:

R^1 is




US application Serial No. 09/840,503
Attorney Docket No. QA231

and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




US application Serial No. 09/840,503
Attorney Docket No. QA231

and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

US application Serial No. 09/840,503
Attorney Docket No. QA231


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is


US application Serial No. 09/840,503
Attorney Docket No. QA231



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




US application Serial No. 09/840,503
Attorney Docket No. QA231

and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:


R¹ is



and R³ is hydrogen;

a compound of formula (V) wherein:

R¹ is




and R³ is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:

R^1 is




and R^3 is hydrogen;

US application Serial No. 09/840,503
Attorney Docket No. QA231

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

a compound of formula (V) wherein:


R^1 is



and R^3 is hydrogen;

and a compound of formula (V) wherein:





R^1 is








US application Serial No. 09/840,503
Attorney Docket No. QA231

and R³ is hydrogen.





16. (Previously Amended) A compound of Claim 10 or enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts and solvates thereof selected from:








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231






US application Serial No. 09/840,503
Attorney Docket No. QA231








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231








US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231







US application Serial No. 09/840,503
Attorney Docket No. QA231




US application Serial No. 09/840,503
Attorney Docket No. QA231




US application Serial No. 09/840,503
Attorney Docket No. QA231



US application Serial No. 09/840,503
Attorney Docket No. QA231



and



17. (Original) A pharmaceutical composition comprising a compound of Claim 10 and a pharmaceutically acceptable carrier.
18. (Canceled).
19. (Original) A pharmaceutical composition comprising a compound of Claim 12 and a pharmaceutically acceptable carrier.
20. (Original) A pharmaceutical composition comprising a compound of Claim 13 and a pharmaceutically acceptable carrier.
21. (Original) A pharmaceutical composition comprising a compound of Claim 14 and a pharmaceutically acceptable carrier.
22. (Original) A pharmaceutical composition comprising a compound of Claim 15 and a pharmaceutically acceptable carrier.
23. (Original) A pharmaceutical composition comprising a compound Claim 16 and a pharmaceutically acceptable carrier.
- 24.-29. (Canceled)

US application Serial No. 09/840,503
Attorney Docket No. QA231

30. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of claim 10.

31. (Canceled)

32. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of claim 12.

33. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of claim 13.

34. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

35. (Previously Added) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of a phosphodiesterase Type 4 inhibitor and a compound of claim 10.

US application Serial No. 09/840,503
Attorney Docket No. QA231

36. (canceled).

37. (Previously Added) A method of claim 34 wherein: the phosphodiesterase Type 4 inhibitor is [4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone].

38. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of Claim 17.

39. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of Claim 17 and another agent known to be useful in treatment of such disorders.

40. (Previously Added and Amended) A method of treating inosine monophosphate dehydrogenase associated disorders selected from inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex I, herpes simplex II, rheumatoid arthritis, asthma, and transplant rejection comprising: administering to a subject a therapeutically effective amount of a compound of Claim 17 and a phosphodiesterase Type 4 inhibitor.

41. (Previously Added) A method for the treatment or prevention of allograft rejection comprising: administering a therapeutically effective amount of the pharmaceutical composition of Claim 17 and a phosphodiesterase Type 4 inhibitor.